Ekh.Bk
EKH.BK operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
Business. EKH.BK operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
Analyst recommendations
2 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
EKH.BK operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
EKH.BK's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 4.0, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -257.5 million THB, which may indicate that capital expenditures are outpacing operating cash flow.
In terms of profitability, EKH.BK's return on equity (ROE) is 11.06%, and its return on assets (ROA) is 8.91%, both of which are strong indicators of efficient use of equity and assets. The company's gross profit margin is 41.75%, and its operating margin is 25.43%, which are key metrics for assessing the company's operational efficiency and pricing power.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no specific geographic breakdown provided. This lack of diversification may pose a concentration risk, as the company's performance is heavily dependent on a single business line.
EKH.BK's growth trajectory is not explicitly detailed in the provided data, but the company's operating income and net income have shown positive figures, indicating a profitable operation. The company's capital expenditures of -391.0 million THB suggest a significant investment in long-term assets, which could support future growth.
The risk assessment for EKH.BK indicates a low dilution risk, with no significant dilution potential noted in the basic shares outstanding. However, the company's net cash position is negative after subtracting total debt, which could be a concern for liquidity.
Recent events and filings do not provide specific details on EKH.BK's recent activities, but the company's financial statements and analyst estimates suggest a stable but not highly optimistic outlook.
- EKH.BK maintains a conservative capital structure with a low debt-to-equity ratio.
- The company's strong ROE and ROA indicate efficient use of equity and assets.
- The company's free cash flow is negative, which may impact its ability to fund operations and growth.
- EKH.BK's revenue is concentrated in a single segment, posing a concentration risk.
- Analyst estimates suggest a neutral outlook with a mean price target close to the current market price.
- **margin_outlook_rationale**: The company's gross and operating margins are strong, indicating a stable margin outlook driven by efficient operations.
- **rd_outlook_rationale**: No specific R&D outlook is provided, but the company's capital expenditures suggest investment in long-term growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,29 |
| Revenue | —no estimate | —no estimate | 1,4B THB |
| Operating income | —no estimate | —no estimate | 288,4M THB |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- EKH.BK Market data — financials · 2026-05-27
- Ekachai Medical Care PCL Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Amnuay UeaArimitChief Executive Officer, Executive Director